Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
TOJA-CAMBA, FJ; RODRIGUEZ-RODRIGUEZ, MP y GRANDIO-LEIVAS, L. Therapeutic management of invasive aspergillosis in a transplant patient and isavuconazole as a new antifungal alternative. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.4, pp.425-427. Epub 19-Sep-2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x20210004000017.
Opportunistic infections in patients undergoing solid organ transplantation (TOS) are a very important cause of morbidity and mortality. Among them, fungal infections, stand out for their higher mortality. One of the most frequent fungal infections is caused by Aspergillus. There are more than 150 species of Aspergillus, being Aspergillus fumigatus the most common agent of invasive fungal infections in human. Gold standard treatment for invasive aspergillosis in a patient withTOS is voriconazole.
We present the case of a kidney transplanted and immunocompromised patient with severe sepsis of respiratory origin in context of invasive aspergillosis. Interest of this case lies on the multiple pharmaceutical interventions in the patient's complex pharmacological management throughout his stay in the critics unit and satisfactory treatment with isavuconazole, a new antifungal.
Palabras clave : Aspergillus; transplants; sepsis.